Report shows 241 blood cancer drugs in the pipeline

04/29/2013 | Drug Store News

According to the Pharmaceutical Research and Manufacturers of America, as many as 241 blood cancer medications are undergoing clinical development or FDA assessment, 98 of which are dedicated to lymphoma treatment, while 97 are for leukemia, 52 target multiple myeloma and 24 address bone marrow, blood and lymph node malignancies.

View Full Article in:

Drug Store News

Published in Briefs:

SmartBrief Job Listings for Health Care